gip glp-1 dual agonist The Emerging Role of and Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction The Effects of Dual GLP-1/GIP

developed and tested a variety of new aminomethyl-piperidones as potential DPP-4 inhibitors (108)

Evidence for Cardiovascular Safety The DPP-4 inhibitors have not demonstrated any sustained or clinically significant reduction in other cardiovascular risk factors, such as blood pressure or lipids

About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features 2026 Google LLC YouTube, a Google company

With the approved medication now more readily available, there is even less reason to consider risky, unverified sources

The primary endpoint, the between-group change in left ventricular mass, demonstrated that tirzepatide significantly reduced left ventricular mass and paracardiac adipose tissue compared to placebo, with reductions in weight loss

Adapted from Kuritzky et al